Corstasis Therapeutics Appoints Amin Medjamia as VP of Medical Affairs

Corstasis Therapeutics, a late clinical-stage innovator of outpatient therapies to treat fluid overload in patients with cardiorenal and hepatic diseases, appointed Amin M. Medjamia M.D. as Vice President of Medical Affairs.

At Corstasis, he will oversee clinical strategy, scientific communications, and clinical algorithm development via medical engagement as the company advances its lead program Enbumyst (bumetanide nasal spray).

Medjamia is an accomplished physician and medical affairs leader with more than 20 years of experience spanning biotechnology and medical devices. Before joining Corstasis, Medjamia held senior leadership roles at Abiomed, a Johnson & Johnson MedTech company. 

To Johnson & Johnson MedTech, he directed global evidence generation for the company’s portfolio of mechanical circulatory support devices. His leadership contributed to PMA approvals, global reimbursement milestones in France and Japan, and large-scale international randomized controlled trials.

“We are honored to welcome Dr. Medjamia to Corstasis at this critical time,” said Ben Esque, CEO of Corstasis. “His passion and expertise in cardiovascular medicine and evidence strategy will strengthen our ability to develop and deliver new pathways to improve patient outcomes and reduce cost of care.”